Publications by authors named "Courtney Rehak"

Claim this Profile
D
Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease.
Gilbert M Rishton, Gary C Look, Zhi-Jie Ni, Jason Zhang, Yingcai Wang, Courtney Rehak

ACS Med Chem Lett· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
Nicholas J Izzo, Carla M Yuede, Kelsie M LaBarbera, Colleen S Limegrover, Courtney Rehak

Alzheimers Dement· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling the mature CNS: A predictive screening platform for neurodegenerative disease drug discovery.
Kelsie Mozzoni LaBarbera, Colleen Limegrover, Courtney Rehak, Raymond Yurko, Nicholas John Izzo

J Neurosci Methods· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alzheimer's protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity.
Colleen S Limegrover, Harry LeVine, Nicholas J Izzo, Raymond Yurko, Kelsie Mozzoni, Courtney Rehak

J Neurochem· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain-derived α-synuclein.
Colleen S Limegrover, Raymond Yurko, Nicholas J Izzo, Kelsie M LaBarbera, Courtney Rehak

J Neurosci Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
Nicholas J Izzo, Agnes Staniszewski, Lillian To, Mauro Fa, Andrew F Teich, Courtney Rehak

PLoS One· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.
Nicholas J Izzo, Jinbin Xu, Chenbo Zeng, Molly J Kirk, Kelsie Mozzoni, Courtney Rehak

PLoS One· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis